Table 1 Clinicopathologic features of included male breast cancers

From: Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations

Age at diagnosis

Median (range) (years)

60.6 (30.1–85.7)

 

Disease-specific mortality

18

38%

Multifocal

1

2%

Bilateral

1

2%

Tumour size

Median (range) (mm)

17 (2–50)

 

Histologic subtype

Invasive carcinoma – no special type

35

73%

Invasive carcinoma with micropapillary component

7

15%

Invasive papillary carcinoma

5

10%

Invasive lobular carcinoma

1

2%

Grade

1

2

4%

2

25

52%

3

21

44%

ER expression (Allred 0–8)

0

1

2%

1–5

4

8%

6–8

43

90%

PgR expression (Allred 0–8)

0

3

6%

1–5

6

13%

6–8

39

81%

HER2

Amplified

3

6%

Non-amplified

45

94%

Phenotype

Basal

1

2%

Luminal

44

92%

HER2

3

6%

Tumour stage

T1a

1

2%

T1b

3

6%

T1c

24

50%

T2

19

40%

T3

1

2%

Lymphovascular invasion

Absent

23

48%

Present

23

48%

NA

2

4%

Perineural invasion

Absent

25

52%

Present

20

42%

NA

3

6%

Paget's disease of nipple

Absent

37

77%

Present

7

15%

NA

4

8%

Nodal status

N0

20

42%

N1

16

33%

N2

2

4%

NX

10

21%

Margins

Clear

42

88%

Involved

6

13%

DCIS

Absent

15

31%

Present

33

69%

DCIS – nuclear grade

Low

2

6%

Intermediate

20

61%

High

11

33%

  1. Abbreviations: DCIS=ductal in situ carcinoma; ER=oestrogen receptor; PgR=progesterone receptor; NA=not applicable.